TY - JOUR
T1 - Adrenocortical Carcinoma
AU - Rodgers, Steven E.
AU - Evans, Douglas B.
AU - Lee, Jeffrey E.
AU - Perrier, Nancy D.
PY - 2006/7/1
Y1 - 2006/7/1
N2 - ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.
AB - ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.
UR - http://www.scopus.com/inward/record.url?scp=33746378196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746378196&partnerID=8YFLogxK
U2 - 10.1016/j.soc.2006.05.005
DO - 10.1016/j.soc.2006.05.005
M3 - Review article
C2 - 16882496
AN - SCOPUS:33746378196
VL - 15
SP - 535
EP - 553
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
SN - 1055-3207
IS - 3
ER -